Evidence map›Paper›PMID 34983429›Full record

ArticleBMC infectious diseases2022

Surveillance of SARS-CoV-2 antibodies of patients in the local affected area during Wuhan lockdown.

Yueting Tang, Jiayu Sun, Yumeng Yuan, Fen Yao, Bokun Zheng, Gui Yang, Wen Xie, Guangming Ye, Zhen Li, Xiaoyang Jiao and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yueting Tang *Department of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Jiayu Sun *Shantou University Medical College, Shantou, Guangdong, China.
Yumeng YuanShantou University Medical College, Shantou, Guangdong, China.
Fen YaoShantou University Medical College, Shantou, Guangdong, China.
Bokun ZhengDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Gui YangDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Wen XieDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Guangming YeCenter for Clinical Gene Diagnosis, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Zhen LiDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
Xiaoyang JiaoShantou University Medical College, Shantou, Guangdong, China. xyjiao@stu.edu.cn.ORCID http://orcid.org/0000-0002-7568-0595
Yirong LiDepartment of Clinical Laboratory, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China. liyirong838@163.com.
Wuhan University · CNShantou University · CN

Funding

key project for anti-2019 novel coronavirus pneumonia from the national key research and development program of china No. 2020YFC0845500National Natural Science Foundation of China No. 81702273science and technology key project of guangdong province: study on the source and epidemiology of covid-19 2020B111107001scientific research project of covid-19 epidemic prevention and control in guangdong universities No.2020KZDZX1087the national key research and development program of china 2018YFE0204500Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund znpy2019064
6 · The paper itself

Abstract

backgroundSerosurveillance is crucial in estimating the range of SARS-CoV-2 infections, predicting the possibility of another wave, and deciding on a vaccination strategy. To understand the herd immunity after the COVID-19 pandemic, the seroprevalence was measured in 3062 individuals with or without COVID-19 from the clinic.

methodsThe levels of SARS-CoV-2 antibody IgM and IgG were measured by the immuno-colloidal gold method. A fusion fragment of nucleocapsid and spike protein was detected by a qualitative test kit with sensitivity (89%) and specificity (98%).

resultsThe seroprevalence rate for IgM and IgG in all outpatients was 2.81% and 7.51%, respectively. The sex-related prevalence rate of IgG was significantly higher (P < 0.05) in women than men. The highest positive rate of IgM was observed in individuals < 20 years of age (3.57%), while the highest seroprevalence for IgG was observed in persons > 60 years of age (8.61%). Positive rates of IgM and IgG in the convalescent patients were 31.82% and 77.27%, respectively, which was significantly higher than individuals with suspected syndromes or individuals without any clinical signs (P < 0.01). Seroprevalence for IgG in medical staff was markedly higher than those in residents. No significant difference of seroprevalence was found among patients with different comorbidities (P > 0.05).

conclusionsThe low positive rate of the SARS-CoV-2 IgM and nucleic acid (NA) test indicated that the SARS-CoV-2 outbreak is subsiding after 3 months, and the possibility of reintroduction of the virus from an unidentified natural reservoir is low. Seroprevalence provides information for humoral immunity and vaccine in the future.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralCommunicable Disease ControlFemaleHumansImmunoglobulin GImmunoglobulin MMalePandemicsSeroepidemiologic StudiesAntibodies, ViralImmunoglobulin GImmunoglobulin MCOVID-19SARS-CoV-2Serosurveillance

Identifiers

PMID34983429
PMCPMC8724638
OpenAlexW4205488432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.